Tweet
Chest. Omega-3 fatty acid supplementation during pregnancy and respiratory symptoms in Children
[Source: Chest, full page: (LINK). Abstract, edited.]
Original Research | March 13, 2014
Omega-3 fatty acid supplementation during pregnancy and respiratory symptoms in Children
Mar?a Consuelo Escamilla-Nu?ez, MSc; Albino Barraza-Villarreal, MSc, PhD; Leticia Hern?ndez-Cadena, MSc, PhD; Efra?n Navarro-Olivos, MD, MSc; Peter D. Sly, MBBS, FRACP, MD, DSc; Isabelle Romieu, MD, MPH, ScD
Author and Funding Information: Instituto Nacional de Salud P?blica, Cuernavaca Morelos M?xico (Escamilla-Nu?ez, Barraza-Villarreal, Hern?ndez-Cadena, Navarro-Olivos, Romieu); WHO Collaborating Centre for Research and Children?s Environmental Health, Curtin University of Technology and Centre for child of Western Australia, Perth, Australia (Sly); International Agency for Research on Cancer, Lyon, France (Romieu)
Correspondence authors: Albino Barraza-Villarreal, MSc, PhD, Instituto Nacional de Salud Publica, Av. Universidad # 655, Col. Santa Mar?a Ahuacatitl?n, C. P. 62100, Cuernavaca, Morelos, M?xico; e-mail: abarraza@correo.insp.mx
Funding source: Supported by National Council of Sciences and Technology CONACYT (Grant number 87121) and by Award Number R01HD058818 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development. The content is solely the responsibility of the authors and does not necessarily represent the official view of the Eunice Kennedy Shriver National Institute of Child Health & Human Development or the National Institutes of Health.
Chest. 2014. doi:10.1378/chest.13-1432 / Published online
Abstract
Background:
Prenatal consumption of omega-3 fatty acids can act as an adjuvant in the development of the immune system and affect the inflammatory response of neonates.
Material and Methods:
We conducted a double-blind, randomized, placebo-controlled trial in Cuernavaca, Mexico. We randomly assigned 1,094 pregnant women (18 to 35 years of age) to receive 400 mg/day of algal Docosahexaenoic acid or placebo from 18 to 22 weeks of gestation through delivery. Birth outcomes and respiratory symptoms information until 18 months was available for 869 mother-child pairs. Questionnaires were administered and maternal blood samples were obtained at baseline. Mother atopy was based on specific IgE levels. During follow-up, information on infants? respiratory symptoms was collected through questionnaires administered at 1, 3, 6, 9, 12 and 18 months of age. Negative binomial regression models were used to evaluate the effect of supplementation on respiratory symptoms in infants.
Results:
Among infants of atopic mothers, a statistically significant protective effect of DHA treatment was observed on phlegm with nasal discharge or nasal congestion [0.78 (95% CI 0.60 to 1.02)] and fever with phlegm and nasal discharge or nasal congestion [0.53 (95% CI 0.29 to 0.99)] adjusting for potential confounders.
Conclusions:
Our results support the hypothesis that DHA supplementation during pregnancy may decrease the incidence of respiratory symptoms in children with a history of maternal atopic.
Clinical Trial Registration:
Randomized clinical trial (Number NCT00646360 ?Effect of Prenatal Supplementation with Omega 3 Fatty Acids in the Infant's Neurobehavioral Development?)
-
--------
Original Research | March 13, 2014
Omega-3 fatty acid supplementation during pregnancy and respiratory symptoms in Children
Mar?a Consuelo Escamilla-Nu?ez, MSc; Albino Barraza-Villarreal, MSc, PhD; Leticia Hern?ndez-Cadena, MSc, PhD; Efra?n Navarro-Olivos, MD, MSc; Peter D. Sly, MBBS, FRACP, MD, DSc; Isabelle Romieu, MD, MPH, ScD
Author and Funding Information: Instituto Nacional de Salud P?blica, Cuernavaca Morelos M?xico (Escamilla-Nu?ez, Barraza-Villarreal, Hern?ndez-Cadena, Navarro-Olivos, Romieu); WHO Collaborating Centre for Research and Children?s Environmental Health, Curtin University of Technology and Centre for child of Western Australia, Perth, Australia (Sly); International Agency for Research on Cancer, Lyon, France (Romieu)
Correspondence authors: Albino Barraza-Villarreal, MSc, PhD, Instituto Nacional de Salud Publica, Av. Universidad # 655, Col. Santa Mar?a Ahuacatitl?n, C. P. 62100, Cuernavaca, Morelos, M?xico; e-mail: abarraza@correo.insp.mx
Funding source: Supported by National Council of Sciences and Technology CONACYT (Grant number 87121) and by Award Number R01HD058818 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development. The content is solely the responsibility of the authors and does not necessarily represent the official view of the Eunice Kennedy Shriver National Institute of Child Health & Human Development or the National Institutes of Health.
Chest. 2014. doi:10.1378/chest.13-1432 / Published online
Abstract
Background:
Prenatal consumption of omega-3 fatty acids can act as an adjuvant in the development of the immune system and affect the inflammatory response of neonates.
Material and Methods:
We conducted a double-blind, randomized, placebo-controlled trial in Cuernavaca, Mexico. We randomly assigned 1,094 pregnant women (18 to 35 years of age) to receive 400 mg/day of algal Docosahexaenoic acid or placebo from 18 to 22 weeks of gestation through delivery. Birth outcomes and respiratory symptoms information until 18 months was available for 869 mother-child pairs. Questionnaires were administered and maternal blood samples were obtained at baseline. Mother atopy was based on specific IgE levels. During follow-up, information on infants? respiratory symptoms was collected through questionnaires administered at 1, 3, 6, 9, 12 and 18 months of age. Negative binomial regression models were used to evaluate the effect of supplementation on respiratory symptoms in infants.
Results:
Among infants of atopic mothers, a statistically significant protective effect of DHA treatment was observed on phlegm with nasal discharge or nasal congestion [0.78 (95% CI 0.60 to 1.02)] and fever with phlegm and nasal discharge or nasal congestion [0.53 (95% CI 0.29 to 0.99)] adjusting for potential confounders.
Conclusions:
Our results support the hypothesis that DHA supplementation during pregnancy may decrease the incidence of respiratory symptoms in children with a history of maternal atopic.
Clinical Trial Registration:
Randomized clinical trial (Number NCT00646360 ?Effect of Prenatal Supplementation with Omega 3 Fatty Acids in the Infant's Neurobehavioral Development?)
-
--------